AZN Trading Analysis - 10/09/2026 04:11 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• AstraZeneca (AZN) recently advanced Phase III oncology trials for a next-generation antibody-drug conjugate, with topline data expected in coming quarters — a potential pipeline catalyst.
• The company reaffirmed full-year guidance at its H1 update, citing resilient demand in its oncology and bioPharmaceuticals segments despite FX headwinds.
• Regulatory scrutiny in the US and EU over drug pricing continues to pose sector-wide pressure on large-cap pharma names including AZN.
• AZN declared a dividend with ex-date of 2026-08-07 (per fundamentals data), maintaining shareholder yield near 1.3%.
• Broader pharma momentum has been mixed as investors rotate between defensives and growth, which may relate to the stock's recent price softness vs. bullish options flow.

Context: Positive pipeline news and steady dividends contrast with the bearish technical picture in the embedded data, while options sentiment shows bullish conviction — a divergence worth monitoring.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for AZN:

• Trailing P/E: 23.60; Trailing EPS: $6.74 — valuation appears moderate for a large-cap pharma with $247.26B market cap.
• Dividend Yield: 1.32% (Rate $2.10); Ex-Dividend Date: 2026-08-07.
• Market Cap: $247,260,943,580.00; Shares Outstanding: 1,550,906,000.00.
• Beta: 0.01 — extremely low sensitivity to market moves per the data.
• 52-Week High: $212.71; 52-Week Low: $153.41 — current price near lower half of annual range.
• Institutional Ownership: 65.81% — majority held by institutions.
• Average Volume: 2,792,000.00; Historical Volatility: 21.65%.
• PEG Ratio, Forward P/E, Forward EPS, Profit Margins, ROE, Debt/Equity, Free Cash Flow, Revenue Growth, Total Revenue: all null/not provided.
• Analyst Consensus & Target Price: not provided (null).

Fundamentals show stable earnings and low beta, but lack of margin/growth data limits depth. The low current price vs 52-week high diverges from the bullish options sentiment and aligns with weak technicals (price below SMAs).

Current Market Position

From embedded minute and daily data:

• Current Price (indicators): $158.66 (2026-10-08 close $158.66).
• Minute bars 2026-10-08 09:30 to 2026-10-09 15:40 show open 159.80, ranged 156.72–160.05 on 10-08; late 10-09 bars stuck near 159.24–159.54 with low volume (e.g., 18,072 at 15:40).
• Daily history: decline from 164.52 (08-27) to 158.66 (10-08); 30-day high 169.35, low 154.81.
• Intraday momentum: flat-to-slightly-down early 10-08, stabilizing near 159.50 by 10-09 close — weak but not accelerating lower.

Technical Analysis

• Price $158.66 below SMA 5 ($158.13? actually above 5 by 0.53), below SMA 20 ($162.67) and SMA 50 ($162.35) — bearish alignment, no golden cross.
• RSI 35.79 — weak momentum, approaching oversold but not extreme.
• MACD -1.42 vs signal -1.14, hist -0.28 — bearish momentum persisting.
• Bollinger: price near lower band ($155.38) vs mid $162.67 — lower-third position, no squeeze signal.
• 30-day range: high $169.35, low $154.81; price at 33% of range — lower quartile.

True Sentiment Analysis (Delta 40-60 Options)

From AZN_options_20261009_1611.json:

Call Volume: $292,620.00 (75.1%) Put Volume: $97,050.00 (24.9%) Total: $389,670.00

• Sentiment: Bullish (Delta 40-60 only; 20 of 818 opts analyzed).
• Call contracts 739 vs put 116; call trades 13 vs put 7 — strong directional call conviction.
• Near-term expectation: upward bias via pure directional options flow.
• Divergence: Technicals bearish (RSI 35.79, MACD neg, price below SMAs) vs sentiment bullish — confirmed by spread recommendation "divergence detected".

Key Price Levels (Observational Only)